Theravance Biopharma (TBPH) Treasury Shares (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Treasury Shares data on file, last reported at $2.4 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $2.4 million, down 47.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (down 47.41% YoY), and the FY2025 annual result was $3.2 million, down 19.04% from the prior year.
• Treasury Shares slipped to $2.4 million in Q1 2026 per TBPH's latest filing, from $3.2 million in the prior quarter.
• Over five years, Treasury Shares peaked at $12.7 million in Q4 2022 and troughed at $2.4 million in Q1 2026.
• A 5-year average of $5.4 million and a median of $4.1 million in 2025 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2022 and 2023: Treasury Shares surged 52.49% in 2022, then sank 68.63% in 2023.
• A 5-year view of Treasury Shares shows it stood at $12.7 million in 2022, then slumped by 68.63% to $4.0 million in 2023, then decreased by 1.01% to $4.0 million in 2024, then dropped by 19.04% to $3.2 million in 2025, then dropped by 26.36% to $2.4 million in 2026.
• Business Quant data shows TBPH's Treasury Shares at $2.4 million in Q1 2026, $3.2 million in Q4 2025, and $3.7 million in Q3 2025.